Idaho legislators advance bill to allow over-the-counter sales of ivermectin

The Idaho Senate State Affairs Committee convened on April 2, 2025, to discuss a significant bill that would allow the sale of ivermectin over the counter without a prescription. Proponents of the bill argue that ivermectin, a drug recognized for its effectiveness in treating parasitic infections, should be more accessible to the public, especially in underserved areas where healthcare resources are limited.

Senator Anthony, who presented the bill, highlighted ivermectin's long history of safe use and its approval by health authorities such as the World Health Organization and the U.S. Food and Drug Administration for specific applications. He noted that many states, including Arkansas and Tennessee, have already made ivermectin available over the counter, and he believes Idaho should follow suit. The senator emphasized that the drug has a low risk of addiction and could alleviate pressure on healthcare providers by allowing individuals to self-treat common conditions.

However, the discussion revealed concerns among some committee members regarding the lack of medical input on the bill. Senator Berndt expressed reservations about moving forward without consulting medical professionals, suggesting that further discussion would be beneficial. Senator Anton acknowledged the need for a thorough process but indicated that there was a growing consensus among legislators to ease restrictions on ivermectin.

The committee also heard testimony from various stakeholders, including Brian Festa, an attorney advocating for the bill, who shared a personal account of a veteran's struggle to obtain ivermectin through traditional channels. Conversely, Pam Eaton, president of the Idaho Retailers Association, raised concerns about the implications for pharmacies, noting that 99% of pharmacists she consulted opposed the bill. She pointed out that ivermectin currently lacks an over-the-counter label and has potential interactions with other medications, which could complicate its sale without proper labeling.

Despite these concerns, Senator Anton clarified that the bill would not mandate pharmacies to sell ivermectin but would simply legalize its sale over the counter. He assured that once the law passes, manufacturers would likely produce ivermectin with appropriate labeling to ensure consumer safety.

The committee's discussions reflect a broader debate about medication accessibility and safety, with the potential for significant implications for public health in Idaho. The bill is set to move forward, but the committee's deliberations underscore the need for careful consideration of the drug's implications for both consumers and healthcare providers.